The Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted Negative Opinion On Approval Of Eisai/Biogen's Lecanemab As Treatment For Early Alzheimer's Disease, Eisai Said It Will Seek Re-Examination Of The Opinion
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted Negative Opinion On Approval Of Eisai/Biogen's Lecanemab As Treatment For Early Alzheimer's Disease, Eisai Said It Will Seek Re-Examination Of The Opinion
歐洲藥品管理局藥品人用藥品委員會對愛薩伊/渤健公司的來開美單抗用於治療早期阿爾茨海默病作出負面意見。愛薩伊表示將尋求重新審查意見。
and work with the relevant authorities to ensure this treatment is available for eligible people living with early AD in the European Union (EU) as soon as possible.
並且與有關當局合作，確保這種治療儘快適用於早期阿爾茨海默病的符合條件的居住在歐盟(EU)的人。